Anti-Mouse CD279 (PD-1) (Clone RMP1-14) – Purified In vivo PLATINUM™ Functional Grade

Pricing & Details

Product No.P372
Clone
RMP1-14
Protein
PD-1
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
Programmed Death-1, CD279, PD 1
Isotype
Rat
IgG2a κ
Applications
B
,
FA
,
WB
Prod No.
Size
Price
Avail.
Qty
Add to cart
P372-1.0 mg
1.0 mg
$198.00
In stock
Max:
Min: 1
Step: 1
P372-5.0 mg
5.0 mg
$355.00
In stock
Max:
Min: 1
Step: 1
P372-25 mg
25 mg
$1,025.00
In stock
Max:
Min: 1
Step: 1
P372-50 mg
50 mg
$1,650.00
In stock
Max:
Min: 1
Step: 1
P372-100 mg
100 mg
$2,220.00
In stock
Max:
Min: 1
Step: 1

Data

Antibody Details

Product Details

Reactivity Species
Mouse
Host Species
Rat
Immunogen
Mouse PD-1 transfected BHK cells
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
<0.5 EU/mg as determined by the LAL method
Purity
≥98% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Clone RMP1-14 recognizes an epitope on mouse PD-1.
Antigen Distribution
PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells.
Background
PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a co-inhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.

Antigen Details

Protein
Ligand/Receptor
PD-L1 (B7-H1), PD-L2
Function
Lymphocyte clonal selection, peripheral tolerance
PubMed
NCBI Gene Bank ID
Research Area
Apoptosis
.
Cancer
.
Cell Biology
.
Cell Death
.
Immunology
.
Inhibitory Molecules
.
Tumor Suppressors

References & Citations

1.) Ardolino, M. et al. (2018) J Clin Invest. 128(10):4654-4668. PubMed
2.) Schreiber, RD. et al. (2017) Cancer Immunol Res. 5(2):106-117.
3.) Honjo, T. et al. (1992) EMBO J. 11:3887.
4.) Gubin et al. (2018) Cell. 175:1014–1030 Journal Link
5.) Renner et al. (2019) Cell Reports. 29:135–150 Journal Link
General Western Blot Protocol

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Cookie Policy
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy.